Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sage Therapeutics’s Postpartum Depression Drug Shows Positive Results

By Stephanie Guzowski | July 12, 2016

Sage Therapeutics announced that its drug, SAGE-547, alleviated symptoms of severe postpartum depression, meeting the primary endpoint of a small Phase 2 study and sending the company’s shares soaring more than 44 percent Tuesday in early trading.

What’s especially significant is the drug’s ability to statistically reduce symptoms of postpartum depression at 60 hours. Currently, there are no specific treatments for postpartum depression. Standard antidepressants can take around four to six weeks to take effect.

Postpartum depression affects up to 1 in 7 women after childbirth. Symptoms include severe anxiety, panic attacks, irritability, reduced concentration, trouble sleeping, and feelings of inadequacy. Approximately 125,000 cases of severe postpartum depression and diagnosed each year in the U.S., estimates Sage Therapeutics.

The trial, which included 21 patients, found 70 percent of women with severe postpartum depression treated with an injection of SAGE-547 achieved complete remission after 60 hours compared to under 10 percent of women treated with a placebo injection.

Moreover, the complete remission was maintained through to the 30-day follow up.

“This is potentially one of the most important clinical findings in the pharmacologic treatment of postpartum depression to date,” Samantha Meltzer-Brody, the study’s investigator, said in a press release.

To determine the drug’s success, study researchers looked at patients’ HAM-D scores, a rating scale used to provide an assessment of depression. After 60 hours, the women treated with SAGE-547 had a 20-point reduction in their HAM-D score, or more than 12 points greater than the women receiving placebo injections.

A patient is said to be in complete remission when a HAM-D score drops to 7 or below. In the trial, seven of the 10 women treated with SAGE-547 achieved a complete remission at 60 days. And at 30 days, those seven women remained in complete remission. Comparatively, one of the 11 women treated with placebo achieved a complete remission at 60 hours, and two women remained in complete remission at 30 days.

All study participants tolerated the drug well with no serious adverse events, according to the report.

The trial follows a study from last year, in which the drug SAGE-547 achieved complete remission of severe postpartum depression in four women. Critics said this prior study was too small to draw conclusive results.

Sage Therapeutics is beginning an expansion study, which will include different doses of the drug and will enroll women with moderate and severe postpartum depression before the end of the year. The company said it will seek regulatory input in developing the medication for this indication.

SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA receptors in the brain. The specific ways in which SAGE-547 targets these GABA receptors is an indicator of the drug’s benefit against central nervous system diseases, including anxiety and postpartum depression.

The company is also testing its drug, SAGE-547, in a Phase 3 study of patients with super-refractory status epilepticus (SRSE), a severe form of epilepsy.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE